NCT03626753

Brief Summary

Many drugs with various mechanisms of action are used for postcaesarean pain relief. Although the response to pain relief is sometimes believed to be individual, it is very important to establish the most effective with the least adverse effects type of oral analgesia for women after caesarean section. Optimal pain control post-caesarean section will benefit not only the mother and her baby, but also a healthcare system. Optimal pain control may shorten the time spent in hospital after caesarean section and, therefore, reduce healthcare costs.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jan 2015

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2015

Completed
3.1 years until next milestone

First Submitted

Initial submission to the registry

July 31, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

August 13, 2018

Completed
Last Updated

August 15, 2018

Status Verified

August 1, 2018

Enrollment Period

6 months

First QC Date

July 31, 2018

Last Update Submit

August 13, 2018

Conditions

Keywords

Painmultimodalanalgesiapostoperativecesarean sectionobstetricAgentsPhysiological effects of drugsopioidParacetamolNSAIDs

Outcome Measures

Primary Outcomes (1)

  • Visual Analogue Scale (VAS) pain

    from 0 - 10 (with 0 being no pain and 10 being the most severe pain imaginable) at rest and coughing or mobilization

    24 hours postoperative

Secondary Outcomes (3)

  • morphine consumption

    24 hours postoperative

  • sides effects

    24 hours postoperative

  • postoperative complications

    24 hours post operative

Study Arms (2)

Oral Group

ACTIVE COMPARATOR

received in post operative period oral analgesia ( "nefopam (Acupan)" 20mg/6h, "piroxicam (piroxan)" 40mg/24h," Acetaminophen (paracetamol)" 1g/6h)

Drug: Nefopam 20 MG/MLDrug: "Acetaminophen, (paracetamol)" 500Mg TabDrug: (Piroxicam "piroxan") 20 MG Oral Tablet

Intravenous group

ACTIVE COMPARATOR

received in post operative period intravenous analgesia ( "nefopam (Acupan)" 20mg/6h, "piroxicam (piroxan)" 40mg/24h," Acetaminophen (paracetamol)" 1g/6h)

Drug: "Nefopam (Acupan)" 20 MG/ML Injectable SolutionDrug: (Acetaminophen "paracetamol") IV Soln 10 MG/MLDrug: (Piroxicam "piroxan") 20Mg/1mL Injection

Interventions

given by Oral route the dose of 20mg every 6 hours.

Also known as: 2 ampoule
Oral Group

given by intravenous route at the dose of 20mg every 6 hours.

Also known as: 2 ampoule
Intravenous group

2 tablets of "Acetaminophen (paracetamol)" 500Mg Tab administrated orally every 6 hours.

Also known as: 2 tablets
Oral Group

Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.

Also known as: 1 ampoule: 1g
Intravenous group

2 tablets of "piroxicam (piroxan)" administrated orally once per 24 hours.

Also known as: 2 tablets
Oral Group

2 ampoules of (piroxicam "piroxan") administrated intravenously once per 24 hours.

Also known as: 2 ampoules
Intravenous group

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pregnant in singleton pregnancy with gestational age \> 34 weeks
  • American society of anesthesiologists (ASA) physical status I-II.

You may not qualify if:

  • history of gastrointestinal disorders predisposing to bleeding disorders such as ulcerative colitis,
  • Crohn's disease,
  • gastrointestinal cancers or diverticulitis,
  • an active peptic ulcer,
  • an inflammatory gastrointestinal disorder or a gastrointestinal haemorrhage,
  • parturients who present preeclampsia,
  • premature delivery (\<32 weeks),
  • constitutional or acquired coagulopathy,
  • An antecedent of hemorrhage of the delivery,
  • a hemorrhagic complication postoperatively,
  • Anemia (hemoglobin less than 8g / 100ml),
  • conversion of spinal anesthesia into general anesthesia,
  • women with severe medical conditions: renal failure (preoperative creatinine clearance \<30ml / min), heart or liver failure.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre de Maternité de Monastir

Monastir, 5000, Tunisia

Location

Related Publications (2)

  • Mahajan L, Mittal V, Gupta R, Chhabra H, Vidhan J, Kaur A. Study to Compare the Effect of Oral, Rectal, and Intravenous Infusion of Paracetamol for Postoperative Analgesia in Women Undergoing Cesarean Section Under Spinal Anesthesia. Anesth Essays Res. 2017 Jul-Sep;11(3):594-598. doi: 10.4103/0259-1162.206872.

    PMID: 28928554BACKGROUND
  • Mkontwana N, Novikova N. Oral analgesia for relieving post-caesarean pain. Cochrane Database Syst Rev. 2015 Mar 29;2015(3):CD010450. doi: 10.1002/14651858.CD010450.pub2.

    PMID: 25821010BACKGROUND

MeSH Terms

Conditions

Wounds and InjuriesInfectionsPain, PostoperativePainAgnosia

Interventions

NefopamAcetaminophenTabletsInjections

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNeurologic ManifestationsSigns and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

OxazocinesAzocinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesDosage FormsPharmaceutical PreparationsDrug Administration RoutesDrug TherapyTherapeutics

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical doctor, clinical professor of Anesthesiology and intensive care medecine

Study Record Dates

First Submitted

July 31, 2018

First Posted

August 13, 2018

Study Start

January 1, 2015

Primary Completion

June 30, 2015

Study Completion

June 30, 2015

Last Updated

August 15, 2018

Record last verified: 2018-08

Locations